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specific RNA-based adaptor is a common
cellular antiviral strategy that can be
observed in all three domains of life
(tenOever, 2013). Interestingly, the univer-
sal utility of this RNA-based antiviral
strategy is not observed in the domain
eukaryota. For example, although the
entire plant kingdom relies on virus-spe-
cific small interfering RNAs (vsiRNAs)
to defend against viral pathogens, the
chordate phylum of the animal kingdom,
which includes all vertebrates, utilizes a
protein-based strategy that is dependent
on the family of type I interferons (IFN-I)
(tenOever, 2013). Given the evolutionary
necessity for such defense systems,
it seems reasonable to postulate that a
phylum such as chordates would also
utilize RNAi or have at least once used it
in its evolutionary past. This idea is sup-
ported by a number of experimental
observations. First, chordates encode
many of the necessary components for
comprising an antiviral RNAi system
(tenOever, 2013). Second, an inhibitor of
the small RNA machinery was discovered
in vaccinia virus, suggesting that small
RNAs may impose some selective pres-
sure on viruses (Backes et al., 2012).
Third, two recent reports found evidence
for vsiRNA fragments with RNAi-like
signatures in mammalian cells (Li et al.,
2013; Maillard et al., 2013). Although
we would argue that none of the above
observations directly demonstrated anti-
viral function, the collective knowledge
of these findings has recently reignited
the idea thatmammalsmay evoke an anti-
viral RNAi response in addition to utilizing
the well-known IFN-I system.
In an effort to evaluate the contribution
of a mammalian RNAi system with that
of IFN-I, we enabled a poorly replicating
RNA virus with either the capacity to block
IFN-I or RNAi and administered these
viruses to wild-type mice or mice lacking
IFN-I signaling capacity (Backes et al.,798 Cell Reports 9, 798–799, November 6, 202014). This paper, which concluded that
RNAi was not a physiological contributor
to the IFN-mediated antiviral response,
was recently critiqued for the choice of
virus and some of its methodology by
the authors who reported on the RNAi-
like signatures in mammals (Voinnet and
Ding, 2014). Given that there is no evi-
dence for the evolution of a defense
strategy that is virus specific, we contend
that any virus could have been used for
these studies so long as it did not encode
a suppressor of this putative RNAi activ-
ity. Although our small RNA sequencing
(RNA-seq) data could have been pre-
sented in many different ways (with
regards to strand choice), it was the
enrichment of small RNA reads from the
ends of vesicular stomatitis virus (VSV)
that prompted us to move forward with
thismodel system, given that the genomic
ends would be most vulnerable to the
nonprocessive cleavage of mammalian
Dicer. Given that our work is addressing
what should represent a universal antiviral
defense system, how the small RNA data
were presented in the original publication
has no bearing on the overall findings
of the paper. Indeed, we show that in
the absence of Dicer, the small RNAs
mapping to the genomic ends remain,
suggesting that, should antiviral RNAi
exist at all in these cells, it is noncanoni-
cal, and therefore there is little precedent
for how small RNA data from mammals
should be handled. It should also be
noted that the Dicer cells used in this
study were clonally selected from Cre-
treated, Dicer-inducible stem cells so
there was no possibility of wild-type con-
tamination. These cells were used only
as a means of evaluating the biogenesis
of the small virus-derived RNAs detected,
and, given the fact that differentiation is
impaired in the absence of microRNAs
(miRNAs), we intentionally did not refer
to these cells as fibroblasts or stem cells
in the manuscript.14 ª2014 The AuthorsGiven the lack of knowledge concern-
ing antiviral RNAi in mammals, we chose
to evaluate the contribution of small
RNAs in the antiviral response by using re-
combinant viruses and a correlation with
replication levels—the same approach
used in the original studies whose bold
titles declared the general identification
of RNAi in mammals (Li et al., 2013; Mail-
lard et al., 2013). To this end, we infected
wild-type mice and mice lacking an IFN-I
system with VSV expressing a control
cassette, an antagonist to IFN-I, or VP55
(the vaccinia virus antagonist we iden-
tified that results in complete tailing
of Ago-associated small RNAs [Backes
et al., 2012]). We reasoned that, should
mammalian antiviral RNAi exist, VP55
activity evolved to inhibit it. We were
further encouraged by the fact that VSV
expressing VP55 was no longer sensitive
to the exogenous introduction of an
siRNA. Despite this activity, we found
that only the addition of the IFN-I antago-
nist improved virus growth and concluded
that mammalian antiviral RNAi is not a
significant contributor to our IFN-based
antiviral defenses. Although we discuss
in the paper that RNAi activity may be
relevant in some cell types, our data do
support the conclusion that, in vivo, VSV
is not encountering Ago-associated small
RNAs that are inhibiting replication, sug-
gesting that a very large subset of cells,
including monocytes and macrophages,
which are the primary targets of VSV
(Iannacone et al., 2010), fail to evoke an
antiviral RNA response by either miRNAs
or any other Ago-associated small RNAs.
With regards to VSV encoding a sup-
pressor of RNAi silencing, we demon-
strate that VSV can be inhibited by
host miRNAs and by exogenously intro-
duced siRNAs (mimicking the established
antiviral RNAi response). Furthermore,
we demonstrate that VSV can success-
fully process its own miRNA in order to
conclude that the virus does not express
an antagonist of this pathway. Whereas
Voinnet and Ding (2014) argue that a sup-
pressor may exist and simply not have
had the necessary time to inhibit these
processes they failed to acknowledge
that we also successfully prevented
siRNA-mediated targeting when VSV
was enabled with VP55, a known RNAi
antagonist. Given that the virus-derived
small RNAs detected in the original
studies claiming mammalian antiviral
RNAi were never shown to have silencing
potential, any further means for assessing
the presence or absence of a repressor
will demand the capacity to first demon-
strate this activity.
It should also be noted that our paper
is not the only recent publication that
failed to support many of the ideas put
forth for RNAi in mammals. First, the
idea that pluripotent cells utilize antiviral
RNAi because they do not respond
to IFN-I was recently found to be unsub-
stantiated, given that embryonic stem
cells do elicit a transcription response,
albeit somewhat muted, to this antiviral
cytokine family (Wang et al., 2014).
Furthermore, the response to virus infec-
tion has evolved to shut down small RNA
silencing in mammalian cells through the
ribosylation of RNA-induced silencing
complex (Seo et al., 2013). In fact, our
own in vivo data with VSV-VP55 (Backes
et al., 2014) is in complete agreement
with the results generated from Seoet al. (2013). These findings alone would
make mammalian antiviral RNAi in any
cell type with the capacity to respond to
IFN-I seem unlikely. Lastly, in an effort to
determine whether Dicer could elicit an
antiviral activity as it does in other animal
phyla, Bogerd et al. (2014) generated a
Dicer knockout cell line and tested it
against a wide range of viruses. With
the exception of those viruses that
generate their own miRNAs, this paper
demonstrated no increased replication in
the absence of the nuclease with dengue
virus, West Nile virus, yellow fever virus,
sindbis virus, Venezuelan equine enceph-
alitis virus, measles virus, influenza A
virus, reovirus, wild-type VSV, or human
immunodeficiency virus type 1 (Bogerd
et al., 2014).
Reaching a general consensus con-
cerning the relevance of mammalian anti-
viral RNAi will demand contributions from
many groups. Although our studies sup-
port an ‘‘IFN-I-only’’ hypothesis, we do
not deny that this activity may still reside
in certain cells that were not accessible
to VSV and are genuinely incapable of re-
sponding to IFN-I. Indeed, we concluded
that small RNA silencing is not a physio-
logical contributor to the ‘‘IFN-mediated
cellular response.’’ This very topic was
discussed in length in our original publica-
tion (Backes et al., 2014). In closing, these
challenges are a necessary part of the sci-
entific process, and it is clear that timeCell Reports 9, 798–799,and the future work of independent labs
will be needed to better resolve if small
RNAs do significantly contribute to the
mammalian response to virus infection.
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